Evaluation of serum amyloid A, soluble E-selectin and soluble E-cadherin as lung cancer biomarkers
DOI:
https://doi.org/10.18203/2349-3933.ijam20171553Keywords:
Biomarkers, Lung cancer, Serum amyloid A, sE- selectin, sE-cadherinAbstract
Background: Lung cancer screening is a challenge. Sputum cytology, chest X-ray, low dose computed tomography and other screening methods have not proved to be very effective. Serum biomarkers are a new hope in screening of lung cancer. The present study was planned to evaluate sensitivity and specificity of serum levels of amyloid A (SAA), soluble E- selectin (sE-selectin) and soluble E-cadherin (sE-cadherin) as lung cancer biomarkers.
Methods: An observational and cross-sectional study comprised of three groups with 20 subjects each of proven lung cancer cases, patients with non-malignant respiratory diseases and healthy controls. Levels of SAA, sE-selectin and sE-cadherin were measured by solid phase sandwich ELISA. Individual and collective sensitivity and specificity of these biomarkers was analysed and cut off values calculated by receiver operating curves.
Results: A statistically significant difference was found in the median levels (ng/ml) of SAA in patients of lung cancer, other non-malignant respiratory diseases, and healthy controls, the levels (Mean±SD) being 24980.50±6564.14,9961.10±2000.24 and 580.95±334.94 respectively in the three groups. A sensitivity of 80% and specificity of 55% was found when SAA levels of 1068 ng/ml were taken as cut off for screening of lung cancer. However, no significant difference was found in the serum levels of sE selectin and sE cadherin between the three groups. Moreover, significant association of biomarkers could also not be established with lung cancer when they were used in combination.
Conclusions: In this preliminary report from India, SAA has been found to be a promising biomarker in screening for lung cancer.
References
WHO |The global burden of disease: 2004 update [Internet]. WHO. (cited 2015 Sep 27). Available from: http:// www. who.int/ healthinfo/ global_ burden_disease /2004_ report_update /en/
Jamal A, Bray F, Center MM, Ferlay J. Global cancer statististics. CA Cancer J Clin. 2011;61(2):69-90.
Greenberg AK, Lu F, Goldberg JD, Eylers E, Tsay J-C, Yie T-A, et al. CT Scan screening for lung cancer: risk factors for nodules and malignancy in a high-risk urban cohort. PLoS One. 2012;7(7):e39403.
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418-29.
Cho WC. Cancer biomarkers. In: Hayat MA, ed. Methods of cancer diagnosis, therapy and prognosis, 10th edition: New York, Springer; 2010:21-40.
Charalabopoulos K, Gogali A, Dalavaga Y, Daskalopoulos G, Vassiliou M, Bablekos G, et al. The clinical significance of soluble E-cadherin in non-small cell lung cancer. Exp Oncol. 2006;28(1):83-5.
Yildiz PB, Shyr Y, Rahman JSM, Wardwell NR, Zimmerman LJ, Shakhtour B, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007;2(10):893-901.
Swellam M, Raqab HM, Abdalla NA, El-Asmar AB. Soluble cytokeratin-19 and E-selectin biomarkers: their relevance for lung cancer detection when tested independently or in combinations. Cancer Biomark. 2008;4(1):43-54.
Gogali A, Charalabopoulos K, Zampira I, Konstantinidis AK, Tachmazoglou F, Daskalopoulos G, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and E-selectin as lung cancer biomarkers. Chest. 2010;138(5):1173-9.
Cho WCS, Yip TT, Cheng WW, Au JSK. Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 2010;102(12):1731-5.
Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem. 2006;54(1):63-73.
Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-Cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645-54.
Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, et al. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2008;3(2):117-24.
IARC Globocon 2008. Cancer fact sheet lung cancer mortality worldwide in 2008. (Last accessed on 23.11.16). Available from http:// globocon. iarc.fr/ factsheets/cancers/lung.asp.
Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med. 2002;346(2):126-8.
International early lung cancer action program investigators, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763-71.
Biaoxue R, Hua L, Wenlong G, Shaunying Y. Increased serum amyloid A as a potential diagnostic marker for lung cancer: A meta-analysis based on nine studies. BMC Cancer. 2016;16:836.
Charalabopoulos K, Tsambalas S, Syrigos K, Giannakopoulos X, Kalfakakou V, Kiortsis D, et al. Correlation of E-cadherin expression with clinicopathological data in patients suffering from transitional cell carcinoma of the bladder. Exp Oncol. 2003:25;180-5.
Charalabopoulos K, Karachalios G. Adhesion molecules and lung disease. Pneumon Med J. 2000:13:50-6.
Läubli H, Borsig L. Selectins as mediators of lung metastasis. Cancer Microenviron Off J Int Cancer Microenviron Soc. 2010;3(1):97-105.
Guney N, Soydinc HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol Northwood Lond Engl. 2008;25(2):194-200.
Roselli M, Mineo TC, Martini F. Soluble selection levels in patients with lung cancer. Int J Biol Markers. 2002;17(1):56-62.
